Phase 0 to Phase IV: A Full Breakdown of Clinical Trial Phases and Their Purposes
Clinical trials are the backbone of evidence-based medicine — the bridge between scientific discovery and real-world therapy. While the general
The development and approval of generic medicines are crucial to improving accessibility and reducing healthcare costs. However, for a generic drug to be accepted as a substitute for its branded counterpart, it must demonstrate that it is bioequivalent — in other words, that it behaves the same way in the body.
This article examines the scientific and regulatory foundations of bioavailability (BA) and bioequivalence (BE), their role in drug development, and how these parameters are measured and evaluated to ensure therapeutic consistency and patient safety.
Bioavailability refers to the rate and extent to which the active pharmaceutical ingredient (API) becomes available at the site of action after administration.
For orally administered drugs, bioavailability is often expressed as the percentage of the drug that reaches systemic circulation unchanged.
A drug with poor bioavailability may not produce its intended therapeutic effect — making this parameter critical in both innovative and generic drug development.
Bioequivalence means that two drug products (usually a brand-name and its generic) have no significant difference in bioavailability — in terms of both rate (Cmax) and extent (AUC) — when administered at the same molar dose under similar conditions.
Regulatory agencies such as the MHRA, EMA, and FDA require generic manufacturers to demonstrate bioequivalence to the reference product to ensure therapeutic equivalence.
This is essential because a generic product must not only contain the same amount of API but must also deliver it in the same way, within the same time frame, and with the same clinical effect.
Bioequivalence is typically demonstrated through single-dose crossover studies in healthy volunteers, where plasma concentrations of the test (generic) and reference (branded) products are measured over time.
Key parameters include:
To be accepted as bioequivalent, the 90% confidence interval for the ratio of Cmax and AUC (test vs reference) must fall within the regulatory range of 80–125%.
Some drugs — such as narrow therapeutic index (NTI) drugs or modified-release formulations — may require tighter ranges and more complex study designs.
Under certain conditions, regulatory authorities may waive in vivo bioequivalence studies, relying instead on in vitro dissolution data, especially for:
This approach, known as a biowaiver, helps streamline the approval of safe, effective generics without compromising quality standards.
Demonstrating bioequivalence ensures that a generic drug:
Failure to establish BE may result in regulatory rejection, legal challenges, or lack of prescriber confidence.
Bioavailability and bioequivalence are core pillars of modern drug regulation, safeguarding patient outcomes while promoting access to affordable therapies. For generic manufacturers, proving bioequivalence is not just a regulatory hurdle — it’s a scientific guarantee of consistency, reliability, and trust.
As global healthcare systems continue to depend on generics, a clear understanding of BA and BE is more critical than ever — both in the lab and in the clinic.
Clinical trials are the backbone of evidence-based medicine — the bridge between scientific discovery and real-world therapy. While the general
The successful development of any therapeutic agent hinges on more than just identifying a promising molecule. A thorough understanding of
SKD Pharmaceuticals© All Rights Reserved 2017